The DOI matches its Crossref record; 45 of the 50 references it cites were found in a registry or an index; 14 of the 21 sources its claims cite were checked for support.
Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK
Open accessAbstract
Background: Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease. Methods: We conducted a parallel, multicentre, two-arm randomised controlled trial in 16 UK motor neuron disease care centres or clinics. Eligible participants were aged 18 years or older with a diagnosis of definite or laboratory-supported probable, clinically probable, or possible familial or sporadic amyotrophic lateral sclerosis; progressive muscular atrophy; or primary lateral sclerosis; which met the World Federation of Neurology's El Escorial diagnostic criteria. Participants were randomly assigned (1:1) to receive up to eight sessions of ACT adapted for people with motor neuron disease plus usual care or usual care alone by a web-based system, stratified by site. Participants were followed up at 6 months and 9 months post-randomisation. Outcome assessors and trial statisticians were masked to treatment allocation. The primary outcome was quality of life using the McGill Quality of Life Questionnaire-Revised (MQOL-R) at 6 months post-randomisation. Primary analyses were multi-level modelling and modified intention to treat among participants with available data. This trial was pre-registered with the ISRCTN Registry (ISRCTN12655391). Findings: Between Sept 18, 2019, and Aug 31, 2022, 435 people with motor neuron disease were approached for the study, of whom 206 (47%) were assessed for eligibility, and 191 were recruited. 97 (51%) participants were randomly assigned to ACT plus usual care and 94 (49%) were assigned to usual care alone. 80 (42%) of 191 participants were female and 111 (58%) were male, and the mean age was 63·1 years (SD 11·0). 155 (81%) participants had primary outcome data at 6 months post-randomisation. After controlling for baseline scores, age, sex, and therapist clustering, ACT plus usual care was superior to usual care alone for quality of life at 6 months (adjusted mean difference on the MQOL-R of 0·66 [95% CI 0·22–1·10]; d=0·46 [0·16–0·77]; p=0·0031). Moderate effect sizes were clinically meaningful. 75 adverse events were reported, 38 of which were serious, but no adverse events were deemed to be associated with the intervention. Interpretation: ACT plus usual care is clinically effective for maintaining or improving quality of life in people with motor neuron disease. As further evidence emerges confirming these findings, health-care providers should consider how access to ACT, adapted for the specific needs of people with motor neuron disease, could be provided within motor neuron disease clinical services. Funding: National Institute for Health and Care Research Health Technology Assessment and Motor Neurone Disease Association. © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Overview
CoChat Summary
## TL;DR
In this multicentre UK randomised controlled trial of 191 people with motor neuron disease, Acceptance and Commitment Therapy (ACT) plus usual care improved quality of life versus usual care alone at 6 months and 9 months. The intervention was also reported as acceptable, feasible to deliver (including remotely), and not associated with adverse events.
## Key findings
- 191 participants were randomised: 97 to ACT plus usual care and 94 to usual care alone; primary outcome data were available for 155/191 (81%) at 6 months.
- Quality of life on the MQOL-R was higher with ACT plus usual care at 6 months: adjusted mean difference 0·66 (95% CI 0·22 to 1·10), effect size d=0·46, p=0·0031; and at 9 months: 0·76 (0·30 to 1·22), d=0·53, p=0·0011.
- Significant benefits also favored ACT plus usual care for MQOL-R psychological subscale, MQOL-R existential subscale, and modified-HADS depression at both 6 and 9 months, plus AAQ-II at 9 months and EQ-VAS at 6 months.
- Acceptability/safety signals were strong: 70% (68/97) attended all eight sessions, 79% (69/87) rated therapy “satisfactory,” 86% (547/635) of sessions were delivered by video call, and 75 adverse events were reported with 38 serious, but no adverse events were deemed associated with ACT.
## Methods
- Multicentre, parallel-group, two-arm randomised controlled trial in 16 UK motor neuron disease care centres/clinics; participants were randomised 1:1 to ACT plus usual care or usual care alone, with stratification by site.
- Eligible participants were adults with ALS/motor neuron disease variants meeting El Escorial criteria; 191 people with motor neuron disease were recruited between Sept 18, 2019 and Aug 31, 2022. Caregivers could also participate if they were primary informal caregivers.
- Primary outcome was MQOL-R total quality of life score at 6 months; analyses used multi-level mixed-effects models with random effect for therapist and fixed effects for age, sex, and baseline scores, on a modified intention-to-treat basis.
## Limitations
- The paper states that subgroup and mediation findings should be interpreted with caution because of small numbers in depression subgroups, and because mediation assumed psychological flexibility changed before quality of life, which “cannot be verified since they were assessed at the same time.”
- The trial’s primary outcome data were incomplete: 81% (155/191) were available at 6 months, and retention declined further by 9 months (70/97 and 68/94 had MQOL-R data).
- Evident from the text: participants, caregivers, therapists, and treating clinicians could not be masked to allocation because of the nature of the intervention.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 1 Not checked · 90 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“the effect size was based on a clinically meaningful pooled effect size of 0·44 SD reported in a meta-analysis of ACT for mental and physical health conditions versus controls. 38”
What the sources say
- Disputedcites [38] A-Tjak, 2015, A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems, Psychother Psychosom sourceExperimental — accuracy not yet measured
The Results section, “ACT vs. Control Conditions on Primary Outcome Variables” (page unavailable), reports a pooled effect of Hedges’s g = 0.57 across disorders and time points, not 0.44. The paper does analyze ACT for mental and physical health problems versus controls, but the effect size attributed to it is incorrect. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Our findings extend those of previously underpowered studies 10,11 in providing crucial high-quality evidence of the clinical effectiveness of a psychological intervention for people with mo”
What the sources say
- Disputedcites [10] Pagnini, 2017, Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial, Eur J Neurol sourceExperimental — accuracy not yet measured
Citation 10 or 11 is attached to the description of the earlier studies as “underpowered,” not to the citing authors’ claim about their own findings. The cited trial’s Power analysis and sample size section reports a target of 95% power and a planned recruitment of 100 patients; its Results section says 100 were recruited. Although the Discussion reports improved quality of life, our copy does not characterize this trial as underpowered. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [11] Pagnini, 2022, An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial, Amyotroph Lateral Scler Frontotemporal Degener source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“poor quality of life and psychological distress are associated with negative outcomes, including shorter survival time and increased risk of suicide. 4-6”
What the sources say
- Partly supportedcites [4] Fang, 2008, Suicide among patients with amyotrophic lateral sclerosis, Brain sourceExperimental — accuracy not yet measured
The Discussion reports elevated suicide risk among people with ALS and discusses psychological distress, but it does not establish that distress or poor quality of life predicts suicide. The Introduction describes the disease’s usual course; it does not link poor quality of life or distress to shorter survival. No page number is available in our copy. (LLM, conf=0.86)
- Partly supportedcites [5] van Groenestijn, 2016, Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review, Health Qual Life Outcomes sourceExperimental — accuracy not yet measured
The Results section ('Mood associated with QoL'; page not provided) reports that depression was negatively associated with health-related quality of life in seven of eight studies of patients with ALS. It does not report that poor quality of life or psychological distress is associated with shorter survival or increased suicide risk; the Background's general statement about ALS survival does not establish that link. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Johnston, 1999, Mood as a predictor of disability and survival in patients newly diagnosed with ALS/MND, Br J Health Psychol source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This approach has been shown to be beneficial for improving quality of life and psychological wellbeing in other long-term health conditions, including muscle disorders and chronic pain. 14,15”
What the sources say
- Supportedcites [14] McCracken, 2022, New generation psychological treatments in chronic pain, BMJ source
The Characteristics of treatment studies section reports ACT trials involving mixed musculoskeletal pain conditions and fibromyalgia, as well as other chronic pain conditions. It reports improvements in quality of life and depression, supporting the claim’s quality-of-life and psychological-wellbeing outcomes. Page numbers are not available in our copy. (LLM, conf=0.87)
- Supportedcites [15] Rose, 2023, A randomised controlled trial of acceptance and commitment therapy for improving quality of life in people with muscle diseases, Psychol Med source
The Discussion reports that ACT plus standard medical care significantly improved quality of life and mood compared with standard medical care alone in people with muscle diseases. This supports the muscle-disorders example; the sentence’s separate chronic-pain example is not being attributed to this trial. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significant adjusted mean differences in favour of ACT plus usual care compared with usual care alone were also found for the MQOL-R Psychological and Existential subscales and modified-HADS Depression at 6 months and 9 months post-randomisation, AAQ-II at 9 months post-randomisation, and EQ-VAS at 6 months post-randomisation (table 3; figure 2).”
plainstates a causen = 93 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims
Create a free account to see all 103 claims and every source verdict.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 28
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Evidence supports its effectiveness in addressing challenges associated with numerous neurological conditions, including epilepsy, brain tumours, Parkinson's, motor neurone disease, and multiple sclerosis (Alipour, 2019;Gould et al., 2024;Kangas et al., 2015;Zarotti et al., 2021;Zarotti et al., 2022b).”
From “It’s knowing that there are other people and they’ve accepted it”: Patients’ experiences of an acceptance and commitment therapy group intervention for people with neurological conditions (2025) · cites this paper as Gould et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“the recent publication of COMMEND trial, which found ACT plus usual care was clinically effective for maintaining or improving quality of life in people with motor neuron disease (Gould et al., 2024).”
From A Systematic Review of Third-Wave Therapies to Reduce Distress and Improve Wellbeing and Quality of Life in People with Parkinson's Disease. (2025) · cites this paper as Gould et al., 2024
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · cited 7×
“Similarly, our findings might not generalise to all people with motor neuron disease seen in clinics given that, at baseline, two-thirds of participants had been diagnosed with motor neuron disease less than a year previously; ALS functional impairment was fairly mild, on average; and low numbers of participants score…”
InfluentialMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“It was not possible to mask the participants with motor neuron disease, caregivers, therapists, or treating clinicians due to the nature of the intervention.”
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · cited 6×
“38 Statistical analyses were pre-specified in the Statistical Analysis Plan (appendix pp 2–29) before the end of data collection, which was reviewed and approved, along with the trial protocol, by the Trial Steering Committee and the Data Monitoring and Ethics Committee.”
InfluentialRelatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810 · cited 1×
“33 The ZBI assessed whether supporting people with motor neuron disease to engage in ACT placed additional burden on caregivers.”
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“…disease were eligible to participate if aged 18 years and older and they met the World Federation of Neurology’s El Escorial diagnostic criteria 19 for familial or sporadic amyotrophic lateral sclerosis (ALS; which is diagnostically synonymous with motor neuron disease 20 ), or motor neuron…”
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 1×
“39 We also found significant between-group differences in favour of ACT plus usual care for psychological and existential quality of life and depression at both 6 months and 9 months post-randomisation, psychological flexibility at 9 months post-randomisation, and brief health status at 6 months…”
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950 · cited 7×
“…modified for people with motor neuron disease following previous guidance (modified-HADS); 27 Acceptance and Action Questionnaire-II (AAQ-II) 28 for psychological flexibility; EQ-5D-5L and Visual Analogue Scale (EQ-VAS) 29 using mapped tariffs from EQ-5D-5L to EQ-5D-3L 30 for health status,…”
InfluentialCedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307 · cited 5×
“Additional exploratory analyses used structural equation modelling to examine whether the treatment effect, as measured by the MQOL-R at 6 months and 9 months post-randomisation, was moderated by rate of deterioration on the ALS-FRS-R from 0 to 6 months post-randomisation, or mediated by change in psychological flexib…”
InfluentialExternal validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · cited 1×
“48 It is worth noting that being offered an experimental intervention in a randomised controlled trial is not the same as being offered an evidence-based intervention as part of routine clinical practice.”
Psychometric properties of the credibility/expectancy questionnaire
Devilly, G. J., & Borkovec, T. D. (2000) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(00)00012-4 · Cited by 2,295
Cited by
Jing, S., Dai, Z., Wu, Y., Liu, X., Zhang, L., Liu, X., Ren, T., Fu, J., Chen, X., Wang, W., et al. (2025) · BMC Public Health · doi:10.1186/s12889-024-20930-x · Cited by 15
Schriger, S. H., Nurse, C. N., & O’Hayer, C. V. (2025) · Journal of Huntington s Disease · doi:10.1177/18796397251315162 · Cited by 9
“28,29 32 While the literature supporting the effectiveness of ACT is more robust for certain conditions than others (e.g., depression, anxiety, and chronic pain have been particularly well studied), there is clear evidence that ACT can be effective for an array of physical and mental disorders.”
Advances in symptom management and in monitoring disease progression in motor neuron disease
Hobson, E., & McDermott, C. J. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.04.004 · Cited by 6
Self-citationRadaković, R., Carroll, A., Altiero, A., Reichwein, C., Walsh, S. M., Niven, E., Abrahams, S., & Simmons, Z. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12639-z · Cited by 8
“While there has been a recent advance in psychological therapy interventions for pwALS, specifically acceptance and commitment therapy [74], the moderating effect or interplay between cognitive or behavioural impairment and QoL is not clear.”
BackgroundZhang, T., Hui, B. P. H., Ducasse, D., Li, Y., Wang, Y., Hu, J., Tang, W. C. S., & Ke, Y. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000548398 · Cited by 6
Metadata
- Authors
- Gould, R. L., McDermott, C. J., Thompson, B. J., Rawlinson, C. V., Bursnall, M., Bradburn, M., Kumar, P., Turton, E. J., White, D. A., Serfaty, M. A., Graham, C. D., McCracken, L. M., Goldstein, L. H., Al-Chalabi, A., Orrell, R. W., Williams, T., Noad, R., Baker, I., Faull, C., Lambert, T., Chhetri, S. K., Ealing, J., Hanratty, A., Radunovic, A., Gunawardana, N., Meadows, G., Gorrie, G. H., Young, T., Lawrence, V., Cooper, C., Shaw, P. J., Howard, R. J., Andreou, P., Androulaki-Korakaki, D., Blakeley, C., Bridges, G., Campbell, I., Davenport, B., Dee, A., Drewry, N., Flood, J., Fox, A., Girling, M., Glew, R., Hartley, N., Hocking, S., Howell, M., Keetharuth, A., Makin, S., Marsh, J., Mayberry, E., McDonald, A., McPartland, R., Meldrum, S., Mobley, A., Murphy, D., O'Brien, M. C., Oliver, M., Patel, D., Phipps, E., Read, J., Roberts, R., Rooney, N., Smith, C., Statham, J., Thompson, C., Varma, P., Walker, A. M., & Waterhouse, S.
- Affiliations
- University College London (GB)
- NIHR Sheffield Biomedical Research Centre (GB)
- University of Sheffield (GB)
- Barts Health NHS Trust (GB)
- University of Strathclyde (GB)
- Uppsala University (SE)
- King's College London (GB)
- UCL Queen Square Institute of Neurology (GB)
- Derriford Hospital (GB)
- Swansea Bay University Health Board (GB)
- University Hospitals of North Midlands NHS Trust (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- Northern Care Alliance NHS Foundation Trust (GB)
- South Tees Hospitals NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Northern Lincolnshire and Goole Hospitals NHS Foundation Trust (GB)
- Queen Elizabeth University Hospital (GB)
- Corresponding author
- Gould, Rebecca L
- ORCID
- Gould, Rebecca L
- McDermott, Christopher J
- Thompson, Benjamin J
- Rawlinson, Charlotte V
- Kumar, Pavithra
- Turton, Emily J
- Serfaty, Marc A
- Graham, Christopher D
- McCracken, Lance M
- Goldstein, Laura H
- Noad, Rupert
- Baker, Idris
- Faull, Christina
- Chhetri, Suresh K
- Gorrie, George H
- Young, Tracey
- Lawrence, Vanessa
- Cooper, Cindy
- Shaw, Pamela J
- Howard, Robert J
- Drewry, Nicola
- Girling, Melissa
- Keetharuth, Anju
- Makin, Selina
- Mayberry, Emily
- Meldrum, Steven
- Murphy, Donnchadh
- Roberts, Rhys
- Smith, Carla
- Walker, Anne Marie
- Waterhouse, Simon
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 403
- Issue
- 10442
- Pages
- 2381-2394
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4396764086
- Cited by
- 38
- References
- 50
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 6
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by)
- PEARL (University of Plymouth) (submittedVersion)
- Funders
- Motor Neurone Disease Association
- National Institute for Health and Care Research School for Primary Care Research
- Topics
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- acceptance and commitment therapy, motor neuron disease, quality of life, amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis, psychotherapy, mindfulness, behaviour change techniques, usual care comparison, patient-reported outcomes, neurodegenerative disease care, alcoholic beverages
- MeSH terms
- Aged, Female, United Kingdom, Humans, Male, Middle Aged, Quality of Life, Motor Neuron Disease, Treatment Outcome, Acceptance and Commitment Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00533-6
- The paper
- Gould, R. L., McDermott, C. J., Thompson, B. J., Rawlinson, C. V., Bursnall, M., Bradburn, M., Kumar, P., Turton, E. J., White, D. A., Serfaty, M. A., Graham, C. D., McCracken, L. M., Goldstein, L. H., Al-Chalabi, A., Orrell, R. W., Williams, T., Noad, R., Baker, I., Faull, C., . . . Waterhouse, S. (2024). Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK. The Lancet. https://doi.org/10.1016/s0140-6736(24)00533-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.